TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+46.64%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$960M
AUM Growth
+$960M
(-11%)
Cap. Flow
-$331M
Cap. Flow
% of AUM
-34.51%
Top 10 Holdings %
Top 10 Hldgs %
38.43%
Holding
146
New
23
Increased
17
Reduced
40
Closed
47
Top Buys
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
Outlook Therapeutics
OTLK
|
$19.3M |
| 3 |
Immunome
IMNM
|
$17.8M |
| 4 |
Applied Therapeutics
APLT
|
$15.2M |
| 5 |
Evolus
EOLS
|
$14.7M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$91.5M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$65.2M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
$43.4M |
| 4 |
LIAN
LianBio American Depositary Shares
LIAN
|
$41.9M |
| 5 |
Precision BioSciences
DTIL
|
$38.1M |
Sector Composition
| 1 | Healthcare | 98.03% |
| 2 | Technology | 0.94% |
| 3 | Communication Services | 0.51% |
| 4 | Real Estate | 0.32% |
| 5 | Financials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $82M | 8.53% | 2,254,797 +50,000 | +2% | +$1.82M |
|
|
2
Evolus
EOLS
$494M
| $58.1M | 6.05% | 4,147,399 +1,050,000 | +34% | +$14.7M |
|
3
KalVista Pharmaceuticals
KALV
$678M
| $48.9M | 5.09% | 4,125,345 +685,000 | +20% | +$8.12M |
|
4
AnaptysBio
ANAB
$569M
| $30M | 3.12% | 1,330,879 -619,730 | -32% | -$14M |
|
5
Mirum Pharmaceuticals
MIRM
$3.71B
| $29.8M | 3.1% | 1,187,107 +50,000 | +4% | +$1.26M |
|
6
Altimmune
ALT
$338M
| $28M | 2.91% | 2,750,000 | – | – |
|
7
Immunocore
IMCR
$1.62B
| $26.4M | 2.75% | 405,600 | – | – |
|
|
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $24.5M | 2.55% | +700,000 | New | +$24.5M |
|
9
Eli Lilly
LLY
$657B
| $21M | 2.19% | 27,000 -3,000 | -10% | -$2.33M |
|
10
Vaxcyte
PCVX
$4B
| $20.5M | 2.13% | 300,000 | – | – |
|
11
PTC Therapeutics
PTCT
$3.92B
| $20.4M | 2.12% | 700,000 -200,000 | -22% | -$5.82M |
|
|
12
Outlook Therapeutics
OTLK
$37.8M
| $19.3M | 2.01% | +1,619,412 | New | +$19.3M |
|
13
Rocket Pharmaceuticals
RCKT
$354M
| $17.8M | 1.85% | 660,000 +410,000 | +164% | +$11M |
|
|
14
Immunome
IMNM
$828M
| $17.8M | 1.85% | +720,000 | New | +$17.8M |
|
|
AVDL
15
Avadel Pharmaceuticals
AVDL
$1.43B
| $17.7M | 1.84% | 1,047,275 -32,253 | -3% | -$545K |
|
16
Ventyx Biosciences
VTYX
$171M
| $17.1M | 1.78% | 3,100,000 +1,100,000 | +55% | +$6.05M |
|
17
Atea Pharmaceuticals
AVIR
$267M
| $16.5M | 1.71% | 4,076,741 | – | – |
|
|
ELEV
18
DELISTED
Elevation Oncology
ELEV
| $15.7M | 1.63% | 3,060,000 -607,600 | -17% | -$3.12M |
|
|
19
Applied Therapeutics
APLT
$71M
| $15.2M | 1.58% | +2,230,000 | New | +$15.2M |
|
20
Adicet Bio
ACET
$59.9M
| $15.1M | 1.57% | 6,407,400 +5,531,048 | +631% | +$13M |
|
|
MOR
21
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $14.5M | 1.51% | +800,705 | New | +$14.5M |
|
22
CytomX Therapeutics
CTMX
$336M
| $14.1M | 1.46% | 6,450,000 -100,000 | -2% | -$218K |
|
23
Nuvation Bio
NUVB
$1.02B
| $12.9M | 1.35% | 3,551,864 +51,864 | +1% | +$189K |
|
24
GSK
GSK
$79.9B
| $12.9M | 1.34% | 300,000 | – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $12.2M | 1.27% | 547,616 -1,944,164 | -78% | -$43.4M |
|